Publication | Closed Access

Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils

InflammationImmune Effector FunctionsMicrobial PathogensAllergyHigh BindingHuman Neutrophil PhagocytosisGranulocyteImmunologyImmunologic MechanismImmune SystemHumoral ImmunityImmune FunctionInnate ImmunityPhagocyteImmunotherapyMedicinePhagocytotic Neutrophils